A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.

Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic contro...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Chiori Yabuki, Hidetoshi Komatsu, Yoshiyuki Tsujihata, Risa Maeda, Ryo Ito, Kae Matsuda-Nagasumi, Kensuke Sakuma, Kazumasa Miyawaki, Naoya Kikuchi, Koji Takeuchi, Yugo Habata, Masaaki Mori
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24130766/?tool=EBI